Montara Therapeutics Inc. has received $8 million seed financing from several investors to further its development of its ’binary pharmacology’ for diseases of the brain.
G protein-coupled receptor (GPCR) drug discovery and development specialist Confo Therapeutics NV has closed a €60 million (US$65.2 million) series B round that will fund a significant expansion of the inhouse portfolio while it continues to turn the handle on its technology platform to generate more compounds for partnering.
Researchers from Yale School of Medicine, Ionis Pharmaceuticals Inc. and the National Institutes of Health have published data from a study that aimed to identify the signaling pathways involved in cilia-dependent cyst activation (CDCA) in autosomal dominant polycystic kidney disease (ADPKD).
